International consensus diagnostic criteria for neuromyelitis optica spectrum disordersDean M. Wingerchuk, Brian G. Weinshenker, Kay E. Wellik et al.|Neurology|2015Cited by 4.6k
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trialAnthony Traboulsee, Brian G. Weinshenker, Benjamin Greenberg et al.|The Lancet Neurology|2020Cited by 495
Area postrema syndromeEslam Shosha, Sean J. Pittock, Divyanshu Dubey et al.|Neurology|2018Cited by 175
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disordersOlga Ciccarelli, Daniel H. Reich, Jeffrey A. Cohen et al.|The Lancet Neurology|2019Cited by 169
Treatment of MOG antibody associated disorders: results of an international survey.Daniel Whittam, Eric C. Klawiter, A. Jacob et al.|Research Padua Archive (University of Padua)|2020Cited by 139